Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of “Strong Buy” by Analysts

Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus price target of $19.33 for the company, according to Zacks. Zacks has also given Aileron Therapeutics an industry rank of 111 out of 265 based on the ratings given to related companies.

A number of brokerages have commented on ALRN. Canaccord Genuity reiterated a “buy” rating and issued a $19.00 price target on shares of Aileron Therapeutics in a research note on Friday, August 11th. Bank of America Corporation began coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They issued a “buy” rating and a $19.00 price target for the company. William Blair began coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They issued an “outperform” rating for the company. Finally, Jefferies Group LLC began coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They issued a “buy” rating and a $20.00 price target for the company.

TRADEMARK VIOLATION NOTICE: “Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of “Strong Buy” by Analysts” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/19/aileron-therapeutics-inc-alrn-given-consensus-rating-of-strong-buy-by-analysts.html.

A number of hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System acquired a new stake in Aileron Therapeutics in the third quarter valued at $110,000. Vanguard Group Inc. acquired a new stake in Aileron Therapeutics in the second quarter valued at $111,000. Tudor Investment Corp ET AL acquired a new stake in Aileron Therapeutics in the second quarter valued at $112,000. Bank of New York Mellon Corp acquired a new stake in Aileron Therapeutics in the third quarter valued at $135,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Aileron Therapeutics in the third quarter valued at $165,000. Hedge funds and other institutional investors own 12.39% of the company’s stock.

Shares of Aileron Therapeutics (NASDAQ:ALRN) traded up $0.99 on Friday, reaching $12.30. 24,366 shares of the company traded hands, compared to its average volume of 19,010. Aileron Therapeutics has a fifty-two week low of $9.58 and a fifty-two week high of $15.48.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply